At a glance
- Originator Merck & Co
- Class Antiepileptic drugs; Neuroprotectants
- Mechanism of Action Glycine gated NMDA receptor antagonists; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 26 Jun 2001 No-Development-Reported for Epilepsy in United Kingdom (PO)
- 26 Jun 2001 No-Development-Reported for Epilepsy in USA (PO)
- 26 Jun 2001 No-Development-Reported for Neurological disorders in United Kingdom (PO)